MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.

Facial Contouring Through Jaw Exercises: A Report of Two Cases Examining Efficacy and Consumer Expectations.

This study examines the efficacy of jaw exercising products for facial contouring. The two individuals used a commercially available jaw exerciser for approximately three months, following the provided instructions. Neither case reported noticeable changes in jaw appearance based on subjective measurements.

Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles.

Fluorescence detection of breast and prostate cancer cells expressing Tn-antigen, a tumor marker, with lectin (VVL)-labeled nanoparticles. Breast and prostate cancer cells engineered to express high levels of Tn-antigen and non-engineered controls were incubated with VVL-labeled or unlabeled red dye-doped silica-coated polystyrene nanoparticles. The binding to cells was studied with flow cytometry, confocal microscopy, and electron microscopy.

Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity.

Background: Using lectins to target cancer-associated modifications of PSA glycostructure for identification of clinically significant prostate cancers, e.g., Gleason score (GS) ≥ 7, from benign and indolent cancers (GS 6), is highly promising yet technically challenging.

Identification of stemness-related glycosylation changes in head and neck squamous cell carcinoma.

Background: Altered glycosylation is a hallmark of cancer associated with therapy resistance and tumor behavior. In this study, we investigated the glycosylation profile of stemness-related proteins OCT4, CIP2A, MET, and LIMA1 in HNSCC tumors.

Methods: Tumor, adjacent normal tissue, and blood samples of 25 patients were collected together with clinical details.